Health & Biotech
Immutep up 11pc on US fast-track designation for lead drug candidate
Health & Biotech
Here’s where Dimerix has a key advantage in the billion-dollar market for Diabetic Kidney Disease
Health & Biotech
Imugene gains 10pc on cancer vaccine progress; 3 other biotechs getting patents
Health & Biotech
MGC Pharma delivers first batch order to Swiss PharmaCan, notches record sales quarter
Health & Biotech
Exopharm’s great LEAP forward gets an all-clear cheers from Finland’s Red Cross service
Health & Biotech
It looks like 2021 will be the Year of Cannabis Legalisation in the US
Health & Biotech
Creso Pharma welcomes back experienced cannabis executive as New York legalises weed
Experts
ScoPo’s powerplays: Look to Mach7, Volpara and IMEXHS as quarterly reports near
Health & Biotech
Zoono’s Microbe Shield preps for US rollout after successful coronavirus testing, stock pops 50pc
Health & Biotech
HealthKick Podcast: Kazia tackles the curse of US politicians with its innovative drug candidate
Health & Biotech
Creso Pharma to pursue dual listing in USA; announces new psilocybin supplies
Health & Biotech
Weed Week: Oz cannabis revenue expected to double in 2021 as patients soar
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.